NO20005832L - Nye spesielle formuleringer - Google Patents

Nye spesielle formuleringer

Info

Publication number
NO20005832L
NO20005832L NO20005832A NO20005832A NO20005832L NO 20005832 L NO20005832 L NO 20005832L NO 20005832 A NO20005832 A NO 20005832A NO 20005832 A NO20005832 A NO 20005832A NO 20005832 L NO20005832 L NO 20005832L
Authority
NO
Norway
Prior art keywords
new special
special formulations
formulations
new
special
Prior art date
Application number
NO20005832A
Other languages
English (en)
Other versions
NO20005832D0 (no
Inventor
Walter Perkins
Xingong Li
Donald Hirsch
Eric Mayhew
Imran Ahmad
Shaukat Ali
Andrew S Janoff
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of NO20005832D0 publication Critical patent/NO20005832D0/no
Publication of NO20005832L publication Critical patent/NO20005832L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
NO20005832A 1998-05-20 2000-11-17 Nye spesielle formuleringer NO20005832L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8610898P 1998-05-20 1998-05-20
PCT/US1999/010975 WO1999059550A1 (en) 1998-05-20 1999-05-19 Novel particulate formulations

Publications (2)

Publication Number Publication Date
NO20005832D0 NO20005832D0 (no) 2000-11-17
NO20005832L true NO20005832L (no) 2001-01-18

Family

ID=22196324

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005832A NO20005832L (no) 1998-05-20 2000-11-17 Nye spesielle formuleringer

Country Status (18)

Country Link
US (1) US6500461B2 (no)
EP (1) EP1079812A4 (no)
JP (1) JP2002535242A (no)
KR (1) KR20010052368A (no)
CN (1) CN1310612A (no)
AR (1) AR019308A1 (no)
AU (1) AU745015B2 (no)
BR (1) BR9911031A (no)
CA (1) CA2332545A1 (no)
EA (1) EA200001109A1 (no)
EE (1) EE200000693A (no)
ID (1) ID28166A (no)
IL (1) IL139541A0 (no)
NO (1) NO20005832L (no)
PL (1) PL344327A1 (no)
SK (1) SK17422000A3 (no)
TR (1) TR200003435T2 (no)
WO (1) WO1999059550A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
EP1781182B1 (en) 2004-07-08 2019-11-13 PneumRx, Inc. Pleural effusion treatment device
EP1786443B1 (en) 2004-07-19 2018-06-06 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
US20090136937A1 (en) 2007-05-09 2009-05-28 Coleman Matthew A Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
WO2009015037A2 (en) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis IMAGING PARTICLES
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
EP2628727A3 (en) 2007-11-21 2013-12-25 Decode Genetics EHF Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
JP5539993B2 (ja) * 2008-09-23 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 薬物送達のためのナノ担体
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
RU2506266C2 (ru) 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
CN101670095B (zh) * 2009-04-13 2012-05-23 北京大学 一种用于栓塞治疗的药物组合物及其制备方法
KR20120104512A (ko) 2009-07-14 2012-09-21 알바니 몰레큘라 리써치, 인크. 5-ht3 수용체 조절체, 이의 제조 방법, 및 그의 용도
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
WO2011139899A2 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US8895055B2 (en) 2011-12-21 2014-11-25 The Regents Of The University Of California Telodendrimer nanodiscs without apolipoprotein
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
WO2017044899A1 (en) 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
WO2018053316A1 (en) 2016-09-15 2018-03-22 The Regents Of The University Of California Improved hybrid telodendrimers
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
EP3906233B1 (en) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JP2687448B2 (ja) * 1988-06-22 1997-12-08 大正製薬株式会社 イブプロフェン徐放性製剤
JPH0429924A (ja) * 1990-05-28 1992-01-31 Terumo Corp 脂溶性薬物含有注射用製剤
CA2085342A1 (en) 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
CA2141582C (en) 1992-08-05 2003-09-30 Angelo Mario Morella Pelletised pharmaceutical composition
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DK0902783T3 (da) * 1995-09-12 2002-07-22 Liposome Co Inc Hydrolysefremmende, hydrofobe taxanderivater
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same

Also Published As

Publication number Publication date
JP2002535242A (ja) 2002-10-22
AU745015B2 (en) 2002-03-07
ID28166A (id) 2001-05-10
CN1310612A (zh) 2001-08-29
TR200003435T2 (tr) 2001-03-21
AR019308A1 (es) 2002-02-13
EP1079812A1 (en) 2001-03-07
SK17422000A3 (sk) 2001-09-11
NO20005832D0 (no) 2000-11-17
PL344327A1 (en) 2001-10-22
BR9911031A (pt) 2002-01-29
WO1999059550A1 (en) 1999-11-25
US20020034536A1 (en) 2002-03-21
US6500461B2 (en) 2002-12-31
EA200001109A1 (ru) 2001-06-25
IL139541A0 (en) 2004-02-08
CA2332545A1 (en) 1999-11-25
AU4190699A (en) 1999-12-06
EE200000693A (et) 2002-04-15
EP1079812A4 (en) 2001-12-12
KR20010052368A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
NO20005832D0 (no) Nye spesielle formuleringer
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
NO20004240D0 (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
NO20021116L (no) Nye sammensetninger
PT1130966E (pt) Formulacoes antiparasitarias
ID23299A (id) Formulasi-formulasi farmasi
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
DK1109449T3 (da) Mikrokapselformuleringer
ID23761A (id) Trisiklik tersubstitusi
NO20020810D0 (no) Nye fenylpiperaziner
NO20015074L (no) Nye sammensetninger
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
NO20010860D0 (no) Nye forbindelser
ATE232683T1 (de) Mikrokapsel-formulierungen
NO20010861D0 (no) Nye forbindelser
ID23219A (id) Trisiklik tersubstitusi
NO20005857L (no) Nye blandinger
NO20010584D0 (no) Nye forbindelser
NO20011262L (no) Nye forbindelser
DE59912532D1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
DE59911610D1 (de) Substituierte benzoylcyclohexandione

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application